Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Jun

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Can AI Provide an Early Alert for Breast Cancer Before Diagnosis

Urologic Surgeon Sworn in as AMA President

Head and Neck Cancer HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC

Perioperative Serplulimab in PD-L1–Positive Gastric Cancer